Investigational drug · Phase 2
vopimetostat
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "vopimetostat"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "vopimetostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- NSCLC
- RAS Mutation
- MTAP Deletion
- Lung Cancer
- Pancreatic Cancer Metastatic
- Thoracic Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "vopimetostat" as an intervention, largest first.
- TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC PatientsNot yet recruiting
Tango Therapeutics, Inc.Industry
NCT07897734 · 188 participants (planned) · Start Nov 2026 · Primary completion Nov 2031
Drug: vopimetostat; ERAS-0015 · For: PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC and 5 more
- Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLCNot yet recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07938463 · 30 participants (planned) · Start Apr 30, 2027 · Primary completion Nov 30, 2027
Drug: TNG462 vopimetostat; Lorlatinib · For: ALK Positive Non-small Cell Lung Cancer
Sites: Boston, Massachusetts · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for PDAC
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- RMC-9805Phase 23 trials
Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC
- RNK08954Phase 23 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor Cancer, PDAC, KRAS G12D Mutations
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.